The objective of present work was to develop microencapsulated chitosan microspheres for colon specific drug\ndelivery of capecitabine. As reported initially, in-vitro drug release studies showed more drug release through chitosan\nmicrospheres demanded microencapsulation. The system consists of developed chitosan microsphere entrapped within\neudragit FS30D polymer which combines pH dependent solubility of eudragit FS30D polymer and specific biodegradability of\nchitosan microspheres. The microencapsulation was done for optimized formulation CMF9 with eudragit FS 30D by solvent\nevaporation technique at different ratio. The obtained formulations were characterized for particle size, entrapment efficiency\nand surface morphology. The size of eudragit encapsulated microspheres was between 125 and 164 �¼m and the entrapment\nefficiency of microencapsulated formulations varied between 88 to 94% with increasing core-coat ratio. The SEM study showed\nthat microencapsulated chitosan microspheres exhibited smooth surface and spherical shape. In-vitro drug release behavior was\nstudied in different pH medium and the obtained data were subjected to kinetic equations. Less drug release was observed from\nencapsulated microspheres when the medium pH below 7, which is 5 to 10 % after 2 hrs and 12 to 20% after 5 hrs, while when\nthe pH reached 7.4, the coating layer of eudragit began to dissolve and a controlled release of capecitabine was observed. In\nconclusion, this work presents new approach as well as a new system with a great potential for colonic drug delivery.
Loading....